

AGENDA



2025 Margie & Robert E. Petersen
**NEUROENDOCRINE TUMOR
RESEARCH SYMPOSIUM**
BREAKTHROUGHS TODAY, CURES TOMORROW

All times listed are in Eastern Time

Presenting Sponsor: Exelixis

Monday, November 17, 2025

- 5:00–6:00 p.m.** **Registration**
- 6:00–8:00 p.m.** **Welcome Reception & Poster Session – Esplanade Room**
Sponsored by Chimeric Therapeutics

Tuesday, November 18, 2025

- 8:00–9:00 a.m.** **Breakfast & Registration**
- 9:00–9:05 a.m.** **Welcome**
Elyse Gellerman, MHS, NETRF Chief Executive Officer
- 9:05–9:10 a.m.** **Welcome & Meeting Logistics**
Anna Greene, PhD, NETRF Chief Scientific Officer
- 9:10–9:45 a.m.** **Keynote – Advancing Neuroendocrine Tumor Research: Milestones, Innovations, and the Path Forward**
Pamela Kunz, MD, Yale University
- 9:45–10:00 a.m.** **Patient Voice: Arrows in My Quiver**
Nancy Lewis

SESSION 1: NEW THERAPIES & TARGETS

Session Chairs: Justin Annes, MD, PhD and Gregory Way, PhD

- 10:00–10:15 a.m.** **Inhibition of ROS Detoxification to Target GEP-NETs**
Jeffrey Frost, PhD, UT Houston Health Science Center
- 10:15–10:30 a.m.** **BH3-mimetic Drugs Elicit Cell Death of Neuroendocrine Tumors in Preclinical Models: An Emerging Therapeutic Strategy for NETs**
Zoey Wang, MPhil, Sunnybrook Research Institute
- 10:30–10:45 a.m.** **Discussion**
- 10:45–11:15 a.m.** **Coffee Break**
- 11:15–11:30 a.m.** **Tumor Cell Surface Targeting of High-grade Neuroendocrine Carcinomas**
C. Allison Stewart, PhD, University of Texas MD Anderson Cancer Center
- 11:30–11:35 a.m.** **Pharmacologic and Genetic Disruption of SDH Sensitizes Tumor Cells to YM155-Induced DNA Damage**
Qianjin Guo, PhD, Stanford University
- 11:35–11:40 a.m.** **DUSP1 is a Therapeutic Vulnerability in Neuroendocrine Tumors**
Majid Momeny, PhD, UTHealth Science Center
- 11:40–11:55 a.m.** **Discussion**
- 11:55 a.m.–12:10 p.m.** **Group Photo**
- 12:10–1:30 p.m.** **Lunch**
Sponsored Lunch by ITM

SESSION 2: OMICS & TUMOR SUBTYPES

Session Chairs: Chrissie Thirlwell, MBBS, PhD and Talya Dayton, PhD

- 1:30–1:45 p.m.** **Lung NETs in the Genomics Era: Past, Present, and Future of IARC's lungNENomics Project**
Nicolas Alcala, PhD, IARC – WHO
- 1:45–2:00 p.m.** **A Cellular Map of Human Pulmonary Neuroendocrine Diversity and Proliferation**
Christin Kuo, MD, Stanford University
- 2:00–2:15 p.m.** **Spatial Transcriptomics Reveals Local Subtype-specific Identity and Signaling within Multifocal Small Intestinal Neuroendocrine Tumors**
Akitada Yogo, MD, PhD, University of California, San Francisco
- 2:15–2:20 p.m.** **Identification of PABPC Family, NOTCH1 and MTOR as Critical Somatic Mutations in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) from Whole Exome Sequencing (WES) Analysis**
Hui Yu, MD, University of Colorado, Anschutz
- 2:20–2:35 p.m.** **Whole Transcriptome Sequencing of Pancreatic Neuroendocrine Tumors Identifies Recurrent Fusion Genes in BEND2 as a Unique Oncogenic Driver that Correlates with Poor Patient Prognosis**
Aatur Singhi, MD, PhD, University of Pittsburgh
- 2:35–2:50 p.m.** **Discussion**
- 2:50–3:30 p.m.** **Coffee Break**

SESSION 3: TUMOR MICROENVIRONMENT

Session Chairs: Dawn Quelle, PhD and Mauro Cives, MD

- 3:30–3:45 p.m.** **A New Therapeutic Avenue Tackling Liver Metastasis and Antiangiogenic Resistance**
Minah Kim, PhD, Columbia University
- 3:45–4:00 p.m.** **Analysis of the Tumor Microenvironment in Small Intestinal NETs**
Netta Mäkinen, PhD, Dana-Farber Cancer Institute
- 4:00–4:05 p.m.** **Dissecting the Neuroimmune Landscape of Pancreatic Neuroendocrine Tumors with Single-cell Spatial Proteo-transcriptomics**
Jeanna Qiu, AB, Harvard Medical School
- 4:05–4:10 p.m.** **TILs in Pancreatic Neuroendocrine Tumors (PanNETs): Towards Novel Cell Therapy Approaches**
Nada Chaoul, PhD, University of Bari Aldo Moro
- 4:10–4:15 p.m.** **Single-cell Dissection of Cellular Crosstalk and Ligand-Receptor Networks Underlying Grade Transformation in Pancreatic Neuroendocrine Tumors**
Himanshu Singh, PhD, Memorial Sloan Kettering Cancer Center
- 4:15–4:20 p.m.** **Unravelling the Molecular Mechanisms Behind Mesenteric Fibrosis: From Multi-omic Analysis to Target Gene Identification Using a Novel in Vitro 3D Patient-derived Model**
Harry Hodgetts, MSc, University College London
- 4:20–4:35 p.m.** **Discussion**
- 4:35–4:40 p.m.** **Travel Award Presentations**



2025 Margie & Robert E. Petersen
**NEUROENDOCRINE TUMOR
RESEARCH SYMPOSIUM**
BREAKTHROUGHS TODAY. CURES TOMORROW

- 4:40–6:00 p.m.** **Extended Poster Viewing & Happy Hour – Esplanade Room**
Sponsored by ITM
- 6:00 p.m.** **End of Day**

DAY 3 – Wednesday, November 19, 2025

- 8:00–9:00 a.m.** **Breakfast & Registration**
- 9:00–9:05 a.m.** **Welcome**
Anna Greene, PhD, NETRF Chief Scientific Officer
- 9:05–9:20 a.m.** **Patient Voice: The Healing Garden**
Jake Dawson
- 9:20–9:45 a.m.** **Challenge Address: Gaps in Basic & Translational Neuroendocrine Cancer Research**
Iacovos Michael, PhD, Sunnybrook Research Institute & University of Toronto
- 9:45–10:00 a.m.** **Discussion**

SESSION 4: RADIOPHARMACEUTICALS

Session Chairs: Erik Mittra, MD, PhD and Daniel Halperin, MD

- 10:00–10:15 a.m.** **EphA2 Targeting Peptide Radiotheranostics for Lung Neuroendocrine Tumors**
Ajay Kumar Sharma, PhD, Johns Hopkins University
- 10:15–10:30 a.m.** **Enhancer Landscape of Neuroendocrine Tumors Reveals Developmental Signatures with Theranostic Implications**
Yotam Drier, PhD, Hebrew University of Jerusalem
- 10:30–11:00 a.m.** **Coffee Break**
- 11:00–11:15 a.m.** **Results of the COPPER PET in NET Trial: A Randomized, Crossover, Readers Blind, Phase I/II Study Comparing ⁶¹Cu-NODAGA-LM3 and ⁶⁸Ga-DOTATOC for the Detection of Neuroendocrine Tumors**
Guillaume Nicolas, MD, University Hospital Basel
- 11:15–11:30 a.m.** **Computational Design and Preclinical Evaluation of Chelators for the Alpha-Emitter Pb-212**
Dongyoul Lee, PhD, Korea Military Academy
- 11:30–11:35 a.m.** **Testing of Current and Novel FAPI Agents in Neuroendocrine Tumors**
Gina Kaup, BS, University of Michigan
- 11:35–11:50 a.m.** **Discussion**
- 11:50 a.m.–12:20 p.m.** **Break & Lunch**
Sponsored by Perspective Therapeutics



2025 Margie & Robert E. Petersen
**NEUROENDOCRINE TUMOR
RESEARCH SYMPOSIUM**
BREAKTHROUGHS TODAY. CURES TOMORROW

SESSION 5: BIOLOGY AND MODEL SYSTEMS

Session Chairs: Iacovos Michael, PhD and James Bibb, PhD

- 12:20-12:35 p.m.** **Using Patient-derived Tumor Organoids to Uncover Mechanisms of Pulmonary NET Progression**
Talya Dayton, PhD, European Molecular Biology Laboratory (EMBL), Barcelona
- 12:35-12:50 p.m.** **Variable GLP-1 Receptor Expression Across Diverse Neuroendocrine Neoplasms: Implications for Incretin Therapies**
Andrew Bellizzi, MD, University of Iowa
- 12:50-1:05 p.m.** **Sortilin in Functional Neuroendocrine Tumors: Marker and Target**
Felix Bolduan, MD, Charité Universitätsmedizin Berlin
- 1:05-1:10 p.m.** **Establishing and Characterizing New Pancreatic Neuroendocrine Tumor Mouse Models**
Shifei (Samuel) Wu, BSc, Lunenfeld Tanenbaum Research Institute/
University of Toronto
- 1:10-1:15 p.m.** **miR-375 Targets YAP to Regulate Neuroendocrine Differentiation and Tumorigenesis in PanNEN Cells**
Tashifa Imtiaz, BScH, MSc, Queen's University
- 1:15-1:20 p.m.** **The genetic evolution of low to high-grade progression in pancreatic neuroendocrine tumors**
Nancy Joseph, MD, PhD, University of California, San Francisco
- 1:20-1:35 p.m.** **Discussion**
- 1:35-1:45 p.m.** **Knowledge Gained, Horizons Ahead – Close of Meeting**
Mauro Cives, MD, University of Bari Aldo Moro



2025 Margie & Robert E. Petersen
**NEUROENDOCRINE TUMOR
RESEARCH SYMPOSIUM**
BREAKTHROUGHS TODAY. CURES TOMORROW